Tissue Diagnostics

Tissue Diagnostics Market Outlook

The global Tissue Diagnostics Market was valued at approximately USD 3.5 billion in 2023 and is projected to reach about USD 5.8 billion by 2035, growing at a CAGR of 5.2% during the forecast period. This substantial growth is driven by several factors, including the increasing prevalence of cancer across the globe, advancements in diagnostic technologies, and the rising demand for personalized medicine. Furthermore, the growing emphasis on early diagnosis and screening of diseases, coupled with continuous innovations in tissue diagnostics, significantly contributes to market expansion. The increasing number of partnerships between research institutions and diagnostic companies is also expected to bolster market growth. As healthcare infrastructure improves and more sophisticated diagnostic solutions are introduced, the Tissue Diagnostics Market is set to thrive in the coming years.

Growth Factor of the Market

The growth of the Tissue Diagnostics Market is primarily influenced by the increasing incidence of cancer, wherein early detection plays a crucial role in improving patient outcomes. According to the World Health Organization, cancer cases have surged dramatically, necessitating advanced diagnostic tools that can enable precise identification and stratification of tumors. Additionally, technological advancements, particularly in immunohistochemistry and digital pathology, are enhancing diagnostic accuracy and efficiency, thereby driving adoption rates among healthcare providers. There is also a global trend towards personalized medicine, which requires comprehensive tissue analysis to tailor treatments to individual patients. Furthermore, the push for better healthcare outcomes through government initiatives and funding for cancer research is stimulating innovation in diagnostic methodologies, establishing a robust framework for market growth.

Key Highlights of the Market

• The market is projected to reach USD 5.8 billion by 2035, reflecting a CAGR of 5.2%.
• Increasing prevalence of cancer worldwide is a significant driver of market growth.
• Technological advancements in diagnostic tools are enhancing accuracy and efficiency.
• The trend towards personalized medicine is leading to increased demand for tissue diagnostics.
• Government initiatives and research funding are promoting innovation in diagnostic methodologies.

By Product Type

Instruments:

Instruments play a pivotal role in the Tissue Diagnostics Market, encompassing a wide array of devices essential for sample preparation, staining, and analysis. These instruments, including microtomes, automated staining systems, and imaging systems, facilitate the efficient processing of tissue samples, ensuring high-quality results. The demand for advanced instruments is on the rise, driven by their ability to enhance workflow efficiency and reduce turnaround times in diagnostic laboratories. Furthermore, the introduction of cutting-edge technologies and automation in histopathology is reshaping this segment, allowing pathologists to achieve higher throughput and improved accuracy in diagnosis. As healthcare facilities continue to invest in modern laboratory infrastructure, the instruments segment is expected to experience significant growth in the coming years.

Consumables:

Consumables are critical components of the Tissue Diagnostics Market, comprising reagents, antibodies, staining solutions, and other materials necessary for laboratory procedures. The demand for consumables is closely tied to the volume of diagnostic tests performed, which is expanding alongside the rising incidence of cancer and other diseases requiring histopathological evaluation. Moreover, advancements in consumable products are leading to increased efficiency and effectiveness in tissue staining and analysis, further driving market growth. Manufacturers are focusing on developing novel reagents and kits that enhance specificity and reduce background staining, which is vital for accurate diagnosis. Consequently, this segment is poised for robust growth as laboratories increasingly adopt high-quality consumables to improve diagnostic precision.

Software:

Software solutions within the Tissue Diagnostics Market facilitate data management, image analysis, and reporting, playing an indispensable role in modern pathology. With the rise of digital pathology, software applications are being increasingly utilized to enhance workflow efficiency and diagnostic accuracy. These solutions enable pathologists to analyze digital images of tissue samples, making it easier to identify abnormalities and make informed decisions. The growing trend towards telepathology and remote consultations is further propelling the demand for sophisticated software tools that support file sharing and collaboration among healthcare professionals. Additionally, the integration of artificial intelligence in pathology software is revolutionizing the field, allowing for more precise diagnostic interpretations. As such, the software segment is expected to witness substantial growth in the coming years.

By Technology

Immunohistochemistry:

Immunohistochemistry (IHC) is one of the most widely used techniques in tissue diagnostics, allowing for the visualization of specific proteins within tissues. This method utilizes antibodies that bind to target antigens, facilitating the identification and characterization of cells in tissue samples. The IHC segment is growing rapidly, driven by its crucial role in cancer diagnosis and the development of targeted therapies. With advancements in antibody technology and detection methods, IHC is becoming increasingly reliable and efficient. Furthermore, the expanding application of IHC in research and clinical settings, particularly in oncology and personalized medicine, is enhancing its adoption rates. As researchers and clinicians continue to seek more precise diagnostic tools, the IHC technology segment is expected to expand significantly.

In Situ Hybridization:

In Situ Hybridization (ISH) is a powerful technique used to detect specific nucleic acid sequences within fixed tissues, providing insight into gene expression and chromosomal abnormalities. This technology is particularly valuable in the diagnosis of various cancers as it aids in the identification of genetic markers and alterations. The ISH segment is witnessing growth due to its increasing application in personalized medicine, where understanding genetic profiles is essential for treatment decisions. Additionally, advancements in ISH technologies, including the development of more sensitive probes and improved imaging techniques, are enhancing its application in clinical diagnostics. As the demand for precise molecular diagnostics rises, the ISH technology segment is positioned for robust growth in the years ahead.

Digital Pathology:

Digital pathology is emerging as a transformative technology within the Tissue Diagnostics Market, allowing pathologists to digitize and analyze tissue samples via high-resolution images. This approach enhances the workflow by facilitating remote consultations, archiving, and sharing of diagnostic information. The digital pathology segment is gaining traction as it addresses the challenges associated with traditional microscopy, such as limited accessibility and high variability in interpretations. The growing acceptance of telemedicine and the need for collaborative diagnostics in oncology are further fueling the demand for digital pathology solutions. As technological advancements continue to improve image acquisition and analysis capabilities, this segment is expected to experience significant growth in the coming years.

Special Staining:

Special staining techniques play a vital role in histopathology, enabling the visualization of specific cellular components and tissue characteristics. These techniques are particularly useful for identifying particular types of cells, microorganisms, and tissue structures, enhancing diagnostic accuracy. The special staining segment is witnessing growth due to its essential applications in cancer diagnosis and research. With the increasing complexity of tissue samples and the need for nuanced analyses, special staining techniques are becoming more indispensable in clinical laboratories. Furthermore, ongoing research and development in staining methodologies are leading to innovations that improve specificity and reliability, contributing to the expansion of this market segment.

By Application

Breast Cancer:

The application of tissue diagnostics in breast cancer is significant, as accurate diagnosis is crucial for determining appropriate treatment strategies. Techniques such as immunohistochemistry and genetic profiling are used to assess tumor characteristics, which directly influence patient management. The rising incidence of breast cancer globally is propelling demand for advanced diagnostic solutions. As awareness about early detection and targeted therapies grows, the need for precise tissue diagnostics is becoming increasingly critical in managing breast cancer cases. Furthermore, ongoing research into biomarkers and personalized treatment options is expected to bolster the adoption of advanced diagnostic technologies in this application area.

Lung Cancer:

Lung cancer is one of the leading causes of cancer-related deaths, making effective tissue diagnostics essential for timely intervention. The application of diagnostic techniques such as molecular testing, immunohistochemistry, and histopathology plays a pivotal role in identifying specific subtypes of lung cancer, which is vital for informing treatment decisions. As the understanding of lung cancer biology evolves, the demand for advanced diagnostic tools that assist in the detection of genetic mutations and biomarkers is expected to rise. This application segment is poised for growth due to increasing awareness of the importance of early diagnosis and the development of targeted therapies, further solidifying the role of tissue diagnostics in lung cancer management.

Colorectal Cancer:

Colorectal cancer remains a significant health concern globally, necessitating effective diagnostic approaches for early detection and treatment. Tissue diagnostics are integral to the evaluation and management of colorectal cancer, with techniques such as immunohistochemistry and molecular profiling aiding in the characterization of tumors. The increasing prevalence of colorectal cancer, along with a growing emphasis on screening and preventive measures, is driving demand for advanced diagnostic solutions in this application area. Moreover, the adoption of personalized medicine in colorectal cancer treatment, targeting specific genetic mutations, is further increasing the reliance on tissue diagnostics, positioning this segment for considerable growth.

Lymphoma:

The application of tissue diagnostics in lymphoma is critical for accurate diagnosis and classification of this heterogeneous group of malignancies. Immunohistochemistry is widely used to identify specific markers that differentiate between various types of lymphoma, informing treatment decisions. The rising incidence of lymphoma worldwide, coupled with an increased understanding of its molecular characteristics, is propelling demand for advanced diagnostic techniques. As research continues to unveil the complexity of lymphomas, the role of tissue diagnostics in providing precise and timely diagnoses is becoming more pronounced. Consequently, this application segment is set to experience significant growth, driven by the need for tailored treatment approaches.

Prostate Cancer:

Prostate cancer is one of the most prevalent cancers among men, making effective tissue diagnostics essential for accurate diagnosis and treatment planning. Techniques such as biopsy analysis and immunohistochemistry are critical for identifying tumor characteristics and guiding therapy decisions. The increasing incidence of prostate cancer, along with advancements in diagnostic technologies, is fueling the demand for sophisticated tissue diagnostics in this application area. Additionally, the growing focus on personalized medicine and precision oncology is further enhancing the importance of accurate tissue analysis for prostate cancer. As awareness of prostate cancer screening and early detection continues to rise, the tissue diagnostics market in this application segment is expected to see significant growth.

By End User

Hospitals:

Hospitals represent a key end-user segment in the Tissue Diagnostics Market, given their critical role in patient diagnosis and treatment. Hospitals are increasingly adopting advanced tissue diagnostic technologies to enhance their diagnostic capabilities and improve patient outcomes. With a growing patient population and rising demand for histopathological services, hospitals are investing significantly in modernizing their laboratory infrastructure. Furthermore, the presence of specialized pathology departments within hospitals facilitates the accurate diagnosis of complex cases, driving the demand for advanced diagnostic tools. As hospitals continue to prioritize quality patient care and diagnostic precision, the tissue diagnostics market is poised for substantial growth in this segment.

Diagnostic Laboratories:

Diagnostic laboratories play a vital role in the Tissue Diagnostics Market by providing essential histopathological services to healthcare providers. These laboratories are increasingly adopting advanced technologies to improve diagnostic efficiency and accuracy. The rising demand for specialized diagnostic tests, particularly in oncology, is driving the growth of this segment. Moreover, collaborations between diagnostic laboratories and healthcare institutions are enhancing service delivery and expanding access to cutting-edge diagnostic solutions. As the volume of tissue samples for analysis continues to rise, diagnostic laboratories are expected to invest in modern equipment and technologies, positioning this segment for significant growth in the coming years.

Academic Institutes:

Academic institutes are essential contributors to the Tissue Diagnostics Market, focusing on research and education in pathology and related fields. These institutions conduct pioneering research that drives innovation in diagnostic methodologies and technologies. The growing emphasis on research in cancer biology and pathology is propelling demand for advanced tissue diagnostic techniques within academic settings. Furthermore, partnerships between academic institutes and the healthcare industry are facilitating the translation of research findings into clinical practice, thereby enhancing the overall quality of diagnostics. As funding for cancer research continues to increase, academic institutes are expected to play a crucial role in advancing tissue diagnostics, contributing to market growth.

By Region

The Tissue Diagnostics Market is witnessing significant growth across various regions, with North America leading the charge. North America accounted for approximately 40% of the global market share in 2023 due to the presence of advanced healthcare infrastructure, high funding for cancer research, and a growing number of diagnostic laboratories. The region is expected to maintain its dominance, with a projected CAGR of 5.0% through 2035, driven by increasing cancer prevalence and technological advancements in diagnostic tools.

Europe holds the second-largest share of the Tissue Diagnostics Market, encompassing around 28% of the global market in 2023. The region is characterized by a strong emphasis on research and innovation in healthcare, alongside supportive government policies promoting early cancer detection and diagnosis. As European countries continue to invest in advanced healthcare technologies and infrastructure, the demand for tissue diagnostics is anticipated to grow steadily. Meanwhile, the Asia Pacific region is emerging as a lucrative market, expected to witness the highest growth rate over the forecast period, fueled by rising healthcare expenditures, increasing awareness of early diagnosis, and the growing prevalence of cancer.

Opportunities

The Tissue Diagnostics Market presents a multitude of opportunities, particularly in emerging economies where healthcare infrastructure is rapidly evolving. As countries in the Asia Pacific and Latin America regions invest in modernizing their healthcare systems, there will be increased demand for advanced tissue diagnostic technologies. This creates an opportunity for manufacturers and service providers to establish a foothold in these growing markets by offering innovative solutions tailored to local needs. Moreover, the growing trend toward personalized medicine is driving the need for precise diagnostics, presenting an opportunity for companies to develop and market specialized diagnostic products that cater to this trend. Collaborative partnerships between diagnostic companies and local healthcare providers can further enhance market penetration and facilitate the adoption of advanced diagnostic practices in these regions.

Additionally, advancements in technology, particularly in digital pathology and artificial intelligence, are opening new avenues for growth in the Tissue Diagnostics Market. These technologies enhance the efficiency and accuracy of diagnostic processes, making them increasingly attractive to healthcare providers. As the healthcare industry continues to evolve, there is a growing recognition of the importance of integrating digital solutions into diagnostic workflows. Companies that invest in research and development to innovate and improve diagnostic technologies will be well-positioned to capitalize on this trend. Furthermore, the increasing focus on preventive healthcare and early detection of diseases is likely to drive the demand for tissue diagnostics, creating further opportunities for market players.

Threats

The Tissue Diagnostics Market is not without its challenges, as various factors pose threats to its growth. One significant threat is the rapid pace of technological advancements, which can create uncertainty for companies that may struggle to keep up. As diagnostic technologies evolve swiftly, there is a risk of obsolescence for existing products, leading to increased pressure on manufacturers to innovate continuously. Additionally, stringent regulatory requirements and compliance issues in different regions can complicate market entry for new players and innovation in diagnostic products. Ensuring compliance with these regulations can be costly and time-consuming, thereby affecting the profitability of companies operating in the market. Moreover, the growing prevalence of alternative diagnostic methods, such as liquid biopsy and molecular testing, presents a competitive threat to traditional tissue diagnostics, necessitating a strategic response from industry players.

Restraining factors also play a crucial role in shaping the market landscape. High costs associated with advanced tissue diagnostic technologies can limit accessibility for smaller healthcare facilities and laboratories, particularly in developing regions. This disparity in access can hinder the widespread adoption of innovative diagnostic solutions, affecting overall market growth. Furthermore, the ongoing challenges related to the skilled workforce in pathology can impede market advancement, as the availability of trained professionals is essential for effective tissue diagnostics. Addressing these restraints will be vital for companies seeking to expand their market presence and meet the growing demands for tissue diagnostic services.

Competitor Outlook

• Roche Holding AG
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Agilent Technologies, Inc.
• Leica Biosystems
• F. Hoffmann-La Roche AG
• Merck KGaA
• Hologic, Inc.
• Siemens Healthineers
• Philips Healthcare
• Becton, Dickinson and Company
• PerkinElmer, Inc.
• Genomic Health, Inc.
• Quest Diagnostics Incorporated
• Cardinal Health, Inc.

The competitive landscape of the Tissue Diagnostics Market is characterized by a mix of established players and emerging companies, all vying for market share in this rapidly growing field. Major companies are investing heavily in research and development to introduce innovative products that cater to the evolving needs of healthcare providers. Strategic partnerships, mergers, and acquisitions are prevalent in the market as companies seek to expand their product portfolios and enhance their technological capabilities. Additionally, the emphasis on personalized medicine is prompting diagnostic companies to focus on developing targeted diagnostic solutions, thereby intensifying competition within the market. As a result, a dynamic environment is emerging, where companies must continuously innovate to remain competitive and meet the demands of healthcare professionals.

Roche Holding AG is a key player in the Tissue Diagnostics Market, recognized for its extensive portfolio of diagnostic products and commitment to innovation. The company has made significant strides in the field of immunohistochemistry and molecular diagnostics, positioning itself as a leader in cancer diagnostics. Roche's continuous investment in research and development, along with its strategic collaborations with healthcare institutions, has allowed it to maintain its competitive edge. The company's emphasis on personalized medicine and targeted therapies further enhances its relevance in the market, making it a formidable competitor.

Thermo Fisher Scientific Inc. is another major player in the Tissue Diagnostics Market, renowned for its comprehensive range of products and services. The company offers advanced instruments, reagents, and software solutions that cater to the needs of diagnostic laboratories and healthcare providers. Thermo Fisher's commitment to innovation is reflected in its consistent introduction of cutting-edge technologies that streamline diagnostic processes and enhance accuracy. With a strong global presence and a diverse portfolio, Thermo Fisher continues to be a significant contributor to the growth of the tissue diagnostics market, addressing the challenges posed by emerging trends and increasing demand for high-quality diagnostic solutions.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Merck KGaA
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Hologic, Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Leica Biosystems
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Roche Holding AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 PerkinElmer, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Philips Healthcare
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Abbott Laboratories
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Genomic Health, Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Siemens Healthineers
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Cardinal Health, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 F. Hoffmann-La Roche AG
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Agilent Technologies, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Becton, Dickinson and Company
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Thermo Fisher Scientific Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Quest Diagnostics Incorporated
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Tissue Diagnostics Market, By End User
    • 6.1.1 Hospitals
    • 6.1.2 Diagnostic Laboratories
    • 6.1.3 Academic Institutes
  • 6.2 Tissue Diagnostics Market, By Technology
    • 6.2.1 Immunohistochemistry
    • 6.2.2 In Situ Hybridization
    • 6.2.3 Digital Pathology
    • 6.2.4 Special Staining
  • 6.3 Tissue Diagnostics Market, By Application
    • 6.3.1 Breast Cancer
    • 6.3.2 Lung Cancer
    • 6.3.3 Colorectal Cancer
    • 6.3.4 Lymphoma
    • 6.3.5 Prostate Cancer
  • 6.4 Tissue Diagnostics Market, By Product Type
    • 6.4.1 Instruments
    • 6.4.2 Consumables
    • 6.4.3 Software

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Tissue Diagnostics Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Tissue Diagnostics market is categorized based on

By Product Type

• Instruments
• Consumables
• Software

By Technology

• Immunohistochemistry
• In Situ Hybridization
• Digital Pathology
• Special Staining

By Application

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Lymphoma
• Prostate Cancer

By End User

• Hospitals
• Diagnostic Laboratories
• Academic Institutes

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Roche Holding AG
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Agilent Technologies, Inc.
• Leica Biosystems
• F. Hoffmann-La Roche AG
• Merck KGaA
• Hologic, Inc.
• Siemens Healthineers
• Philips Healthcare
• Becton, Dickinson and Company
• PerkinElmer, Inc.
• Genomic Health, Inc.
• Quest Diagnostics Incorporated
• Cardinal Health, Inc.